US Government Keeps Lights On But Pharma Priorities For PBM Reform, Rare Diseases Nixed

The FDA will stay open, but its rare disease priority review voucher program will wind down after not being renewed on 20 December. PBM reform and other industry priorities also were nixed at the last minute in an effort to avoid a government shutdown.